Elanco Animal Health (NYSE:ELAN) Updates FY 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 1.100-1.160 for the period, compared to the consensus EPS estimate of 1.070. The company issued revenue guidance of $5.1 billion-$5.1 billion, compared to the consensus revenue estimate of $5.1 billion. Elanco Animal Health also updated its Q3 2026 guidance to 0.190-0.220 EPS.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ELAN shares. Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. Morgan Stanley upped their price target on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 22nd. JPMorgan Chase & Co. raised their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, July 31st. Finally, KeyCorp lifted their price objective on shares of Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and an average price target of $28.82.

Elanco Animal Health Stock Down 8.9%

Shares of ELAN stock traded down $2.33 during trading on Thursday, hitting $23.89. 11,295,325 shares of the company were exchanged, compared to its average volume of 5,440,066. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The firm has a market capitalization of $11.93 billion, a price-to-earnings ratio of -47.62, a P/E/G ratio of 1.67 and a beta of 1.67. The business’s 50-day simple moving average is $24.73 and its 200 day simple moving average is $24.10. Elanco Animal Health has a twelve month low of $15.50 and a twelve month high of $27.98.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same quarter in the prior year, the business earned $0.26 EPS. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, analysts forecast that Elanco Animal Health will post 1.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Rajeev A. Modi acquired 4,911 shares of Elanco Animal Health stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average price of $20.35 per share, with a total value of $99,938.85. Following the completion of the transaction, the insider owned 160,812 shares in the company, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jeffrey N. Simmons bought 4,971 shares of the stock in a transaction on Friday, May 15th. The stock was purchased at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the purchase, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This represents a 2.98% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 1.14% of the company’s stock.

Elanco Animal Health News Summary

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Elanco reported second-quarter adjusted EPS of $0.34, above the $0.27 consensus estimate, while revenue rose 10.2% year over year to $1.368 billion, exceeding expectations of $1.31 billion. Elanco Animal Health Reports Second Quarter 2026 Results
• Positive Sentiment: Management raised full-year 2026 adjusted EPS guidance to $1.10-$1.16 from its prior outlook, increased revenue guidance to $5.09-$5.14 billion, lifted adjusted EBITDA guidance to $1.01-$1.035 billion, and raised its innovation-revenue target to $1.25 billion. Zenrelia reportedly reached blockbuster status. Elanco posts Q2 beat as Zenrelia hits blockbuster status
• Positive Sentiment: KeyCorp raised its price target for ELAN to $30 from $29 and maintained an “overweight” rating, indicating continued analyst confidence in the company’s growth outlook. KeyCorp price target update
• Neutral Sentiment: Third-quarter guidance calls for adjusted EPS of $0.19-$0.22 and revenue of approximately $1.2 billion, broadly in line with consensus. That limited near-term upside may be contributing to the weaker stock reaction.
• Negative Sentiment: Although adjusted results were strong, reported net income was $54 million and reported EPS was $0.11. Elanco also remains leveraged at 3.1 times adjusted EBITDA, so investors may remain cautious about debt reduction and the company’s negative GAAP net margin.
• Neutral Sentiment: A Zacks comparison with Addus HomeCare focuses on relative valuation rather than a new company-specific catalyst, potentially prompting investors to reassess whether ELAN’s recent gains adequately reflect its improved outlook. ADUS vs. ELAN: Which Stock Is the Better Value Option?

Institutional Investors Weigh In On Elanco Animal Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. NewEdge Advisors LLC grew its stake in shares of Elanco Animal Health by 133.7% in the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after buying an additional 627 shares in the last quarter. Uniplan Investment Counsel Inc. bought a new position in Elanco Animal Health during the fourth quarter valued at approximately $41,000. UMB Bank n.a. raised its position in Elanco Animal Health by 31.9% during the fourth quarter. UMB Bank n.a. now owns 5,609 shares of the company’s stock valued at $127,000 after acquiring an additional 1,358 shares in the last quarter. Geneos Wealth Management Inc. lifted its stake in Elanco Animal Health by 53.7% in the second quarter. Geneos Wealth Management Inc. now owns 5,954 shares of the company’s stock valued at $85,000 after acquiring an additional 2,080 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in Elanco Animal Health by 2,532.0% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 6,343 shares of the company’s stock valued at $128,000 after acquiring an additional 6,102 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.